CMS Modified NCD 15 for Prolotherapy and Ligamentous Injections with Sclerosing Agents, Effective January 9, 2026 — Here's What Billing Teams Need to Know

TL;DR: The Centers for Medicare & Medicaid Services modified NCD 15, its national coverage determination for prolotherapy, joint sclerotherapy, and ligamentous injections with sclerosing agents, effective January 9, 2026. The position hasn't changed — CMS still denies reimbursement for these services — but the policy update is now on the books, and your billing team needs to understand exactly what that means before submitting claims.

This is not a new coverage policy. NCD 15 in the CMS Medicare system has long held that prolotherapy, joint sclerotherapy, and ligamentous injections with sclerosing agents are not reasonable and necessary under §1862(a)(1) of the Social Security Act. The January 9, 2026 modification confirms that position stands. If your practice bills these services to Medicare, claim denial is the expected outcome — not an edge case.

The policy does not list specific CPT or HCPCS codes. That creates its own set of billing headaches, which we'll get into below.

---

Quick-Reference Table

Field	Detail Copy
Payer	CMS (Medicare)
Policy	Prolotherapy, Joint Sclerotherapy, and Ligamentous Injections with Sclerosing Agents
Policy Code	NCD 15
Change Type	Modified
Effective Date	January 9, 2026
Impact Level	High — blanket non-coverage for all prolotherapy and sclerosing injection services billed to Medicare
Specialties Affected	Pain management, orthopedics, sports medicine, physical medicine and rehabilitation, interventional spine
Key Action	Review your charge capture and superbill for any prolotherapy or sclerosing injection codes; update patient financial counseling to reflect Medicare non-coverage before billing

---

CMS Prolotherapy Coverage Criteria and Medical Necessity Requirements 2026

NCD 15 is the National Coverage Determination governing Medicare coverage of prolotherapy, joint sclerotherapy, and ligamentous injections with sclerosing agents. The policy sits under the Physicians' Services benefit category.

The CMS position is direct: the medical effectiveness of these therapies has not been verified by scientifically controlled studies. Because of that, the Centers for Medicare & Medicaid Services denies reimbursement on the grounds that these services do not meet the reasonable and necessary standard required by §1862(a)(1) of the Act.

Medical necessity is the core issue here. There is no pathway to coverage under NCD 15 — no diagnostic threshold, no prior authorization process, no documentation package that flips this to a covered service. CMS has made a blanket determination that prolotherapy and sclerosing injections fail the evidence standard. Full stop.

That matters for your billing team because some providers still attempt these claims, hoping for MAC-level exceptions or local coverage determination workarounds. NCD 15 operates at the national level. A National Coverage Determination overrides any local coverage determination that might suggest otherwise. If your Medicare Administrative Contractor hasn't issued guidance contradicting NCD 15, they won't — and they can't.

The January 9, 2026 effective date doesn't introduce new criteria. It reflects a policy modification — likely a formatting or administrative update — that re-confirms the standing denial position. Don't read the modification as a signal that CMS is softening on prolotherapy coverage. It isn't.

---

CMS Prolotherapy Exclusions and Non-Covered Indications

NCD 15 doesn't operate with a list of exclusions carved out from an otherwise covered service. The entire category is excluded. Prolotherapy, joint sclerotherapy, and ligamentous injections with sclerosing agents are non-covered in full, for all indications, under Medicare.

The reason is evidentiary. CMS concluded that scientifically controlled studies have not verified the medical effectiveness of these modalities. That language — "not verified by scientifically controlled studies" — is the standard CMS applies when classifying a service as not reasonable and necessary.

This is a different category than "experimental" or "investigational" in the way some commercial payers use those terms. Commercial payers like Cigna Healthcare or UnitedHealthcare sometimes have investigational clauses that allow for coverage exceptions with prior authorization under a clinical trial or coverage with evidence development pathway. Medicare's NCD 15 does not offer that pathway. The service is simply not covered.

For pain management and orthopedic practices that offer prolotherapy alongside covered services, this distinction matters. Patients asking about Medicare coverage for prolotherapy need a clear answer before services are rendered — not after you've submitted a claim and received a denial.

---

Coverage Indications at a Glance

Indication	Coverage Status	Relevant Codes	Notes Copy
Prolotherapy (all indications)	Not Covered	Not specified in NCD 15	Denied as not reasonable and necessary per §1862(a)(1)
Joint sclerotherapy (all indications)	Not Covered	Not specified in NCD 15	Same statutory basis for denial
Ligamentous injections with sclerosing agents (all indications)	Not Covered	Not specified in NCD 15	No prior authorization pathway exists under this NCD

---

CMS Prolotherapy Billing Guidelines and Action Items 2026

The modification effective date of January 9, 2026 is your trigger to audit current workflows. Here's what to do:

Copy Action Items

If you're in a practice that offers prolotherapy to a mixed payer population, the non-Medicare patients may be covered under commercial plans with different policies. Don't let the Medicare blanket denial create assumptions about commercial coverage. Check each payer's coverage policy separately.

---

CPT, HCPCS, and ICD-10 Codes for Prolotherapy Under NCD 15

No Codes Specified in NCD 15

NCD 15 does not list specific CPT codes, HCPCS codes, or ICD-10-CM diagnosis codes. This is a meaningful gap in the policy. It means CMS has issued a category-level exclusion without tying it to specific procedure codes in the policy document itself.

For prolotherapy billing, this creates a real operational problem. Your team still needs to submit claims with procedure codes — whether for denied claims with an ABN in place, for documentation purposes, or for commercial payer submissions. The policy itself won't guide you on which codes apply.

Here's what that means in practice:

Common procedure codes associated with prolotherapy and sclerosing injections include injection codes in the musculoskeletal and joint injection families. Your MAC may have issued specific claims processing instructions that identify the codes CMS expects to see on denied prolotherapy claims. Check your MAC's local resources directly.

Do not invent or assume code assignments based on this NCD alone. Work with your billing consultant or coding team to confirm the correct procedure codes for your specific services. Then apply those codes consistently — both for claim submission and for ABN documentation.

Because NCD 15 lists no codes, there are no covered CPT, no not-covered CPT, and no ICD-10 codes to reproduce here from the policy data. The table below reflects that accurately.

Code Type	Codes Listed in NCD 15	Notes Copy
CPT	None	Policy applies category-wide; check MAC guidance for applicable codes
HCPCS	None	Same as above
ICD-10-CM	None	No diagnosis-level coverage criteria exist under this NCD

The absence of codes in NCD 15 is not a loophole. It's an administrative reality that puts the burden on your coding team to correctly identify the procedure codes your practice uses for these services — and to handle them accordingly.

---